RESUMO
Nutraceuticals, widely becoming adopted as a catchall term to refer to vitamins, minerals, herbs, and various other supplements, continue to gain popularity among large segments of the population, despite little proof of any benefit of most of these compounds.
Assuntos
Qualidade de Produtos para o Consumidor , Suplementos Nutricionais/efeitos adversos , Marketing de Serviços de Saúde , Suplementos Nutricionais/economia , Aprovação de Drogas , Indústria Farmacêutica/economia , Interações Medicamentosas , Medicina Baseada em Evidências , Conhecimentos, Atitudes e Prática em Saúde , Humanos , Educação de Pacientes como Assunto , Medição de Risco , Resultado do Tratamento , Estados Unidos , United States Food and Drug AdministrationRESUMO
Medicine, including the pharmaceutical and biotechnology industries as well as many clinical practitioners, has recognized the importance of using molecular imaging biomarkers, including those labeled in such a way as to be imaged by positron emission tomography (PET), as tools for predicting outcomes in drug development and creating opportunities for "personalized" medicine, for diagnosing early-stage disease, and for the follow-up of the effectiveness of treatment.(1) However, only one important and widely used PET biomarker is currently approved by the Food and Drug Administration (FDA). If the technology is so important, we can ask why there is such a limitation to the availability of these biomarkers.
Assuntos
Farmacologia Clínica/métodos , Tomografia por Emissão de Pósitrons/métodos , Radioisótopos/química , Compostos Radiofarmacêuticos/química , Didesoxinucleosídeos/química , Didesoxinucleosídeos/farmacocinética , Aprovação de Drogas , Radioisótopos de Flúor , Fluordesoxiglucose F18/química , Fluordesoxiglucose F18/farmacocinética , Humanos , Misonidazol/química , Misonidazol/farmacocinética , Estrutura Molecular , Nitrilas/química , Nitrilas/farmacocinética , Radioisótopos/farmacocinética , Compostos Radiofarmacêuticos/farmacocinética , Estados Unidos , United States Food and Drug AdministrationRESUMO
Welfare recipients in the United States are three times as likely to suffer from depression and anxiety as average Americans. Although affordable pharmacotherapy options are readily available in more affluent parts of society, welfare programs are ineffective in facilitating diagnosis and therapy that could help the affected improve their lives and even ultimately become gainfully employed and off taxpayer-supported welfare programs. To the benefit of all, more "bang for the buck" is within reach with common pharmacotherapy, but the question remains: who will wake up and champion the obvious?
